MAQI2 Anticoagulation Toolkit

Name: MAQI2 Anticoagulation Toolkit
Author: University of Michigan

University of Michigan

DOCUMENTED

Published in academic literature

For:Clinicians & Healthcare Professionals

Free

Download on the App Store

App Summary

The MAQI2 Anticoagulation Toolkit is a clinical reference tool for healthcare practitioners, synthesizing guidelines and research to support safer management of patients on anticoagulants. The associated research identified significant opportunities for quality improvement, with one study (N=6,907) finding that targeted interventions could reduce GI hemorrhage risk in the majority of high-risk patients on warfarin. By operationalizing this evidence, the authors conclude that clinics are better positioned to play a proactive and holistic role in minimizing preventable adverse events.

App Screenshots

MAQI2 Anticoagulation Toolkit screenshot 1 of 7

MAQI2 Anticoagulation Toolkit screenshot 2 of 7

MAQI2 Anticoagulation Toolkit screenshot 3 of 7

MAQI2 Anticoagulation Toolkit screenshot 4 of 7

MAQI2 Anticoagulation Toolkit screenshot 5 of 7

MAQI2 Anticoagulation Toolkit screenshot 6 of 7

MAQI2 Anticoagulation Toolkit screenshot 7 of 7

Detailed Description

Functionality & Mechanism

Developed by the Michigan Anticoagulation Quality Improvement Initiative (MAQI2), this clinical toolkit serves as a point-of-care reference for managing patients on anticoagulation therapy. The interface delivers content derived from established clinical guidelines and consortium-led research. Clinicians can access synthesized recommendations and protocols to support decision-making for complex patient scenarios, including dosing adjustments, risk factor management, and therapy transitions. The system is designed to facilitate safe and effective anticoagulation management in various clinical practice settings.

Evidence & Research Context

The app's development was informed by survey research (N=136) indicating that patients with lower time in therapeutic range (TTR) were receptive to using a mobile support tool for their warfarin therapy.
Its content is grounded in extensive research from the MAQI2 consortium, which has published observational studies identifying predictors of warfarin discontinuation (N=734) and modifiable risk factors for upper GI hemorrhage (N=6,907).
As a product of a statewide quality improvement collaborative, the toolkit is designed to translate evidence-based findings into clinical practice to enhance patient safety and standardize care protocols.

Intended Use & Scope

This toolkit is designed for healthcare practitioners, including physicians, pharmacists, and nurses, who manage patients on anticoagulation therapies. Its primary utility is as a clinical reference and decision-support resource. The tool is an adjunct to, not a substitute for, comprehensive clinical judgment, direct patient evaluation, and adherence to institutional protocols. It is not intended for direct use by patients.

Studies & Publications

4 publications

Peer-reviewed research associated with this app.

Survey/Cross-sectional

Missed opportunities to prevent upper GI hemorrhage: The experience of the Michigan Anticoagulation Quality Improvement Initiative

Kurlander et al. (2019) · Vascular Medicine

Anticoagulation clinics identified opportunities to reduce bleeding risk by deprescribing unnecessary antiplatelet drugs and prescribing protective medications.

The central premise, and promise, of anticoagulation clinics is that they can provide safer and more reliable therapeutic anticoagulation through protocolized drug monitoring and dosing, and thereby minimize the risk of both de novo thromboembolic and hemorrhagic events. Anticoagulated patients are particularly at risk for gastrointestinal (GI) hemorrhage. It is well known that anticoagulants, whether warfarin or direct oral anticoagulants,

Survey/Cross-sectional

Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation: The Michigan Anticoagulation Quality Improvement Initiative Experience

Barnes et al. (2017) · JAMA Cardiology

Tracked warfarin discontinuation rates among atrial fibrillation patients.

The use of warfarin significantly reduces the risk of stroke among patients with atrial fibrillation (AF). Unfortunately, up to 60% of patients discontinue therapy within the first year.1 Prior studies did not assess the quality of warfarin therapy or the occurrence of electrical cardioversion (ECV) or radiofrequency ablation (RFA) as predictors of discontinuation of warfarin therapy. Methods Within the Michigan Anticoagulation Quality

In the Media

MAQI2 Anticoagulation Toolkit App, essential for treating patients requiring anticoagulants

The University of Michigan developed MAQI2 Anticoagulation Toolkit to help clinicians answer difficult questions and make decisions regarding anticoagulation therapy, addressing the complex treatment needs of patients with conditions like atrial fibrillation. The app provides essential guidance for treating patients requiring anticoagulants, particularly given that atrial fibrillation affects an estimated 2.2 million people in the U.S. and is associated with a 5-fold increased risk for stroke.

SteadyhealthRead article

Michigan Anticoagulation Quality Improvement Initiative Offers Provider & Patient Anticoagulation Toolkits

The MAQI2 collaborative developed the MAQI2 Anticoagulation Toolkit to help providers manage anticoagulation patients more safely and effectively, using a downloadable collection of guidelines, protocols, and a mobile app. The toolkit includes patient education resources in multiple languages and is available at www.anticoagulationtoolkit.org. Thousands of providers and patients across the country are currently using the toolkit.

UmichRead article